Fluid biomarkers for proteins relevant to other neurological conditions are becoming available—for example mutant huntingtin for Huntington’s disease or frataxin for Friedreich’s ataxia—although assays for some proteinopathies such as α-synuclein and TDP-43 remain a challenge. This evidence concerns the gene TARDBP and juvenile Huntington disease.